Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
PRJ1-3024
/
MingMed Biotech
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1
(Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1378;
P1/2
Conclusions PRJ1
||||
||||||
PRJ1-3024
/
MingMed Biotech
Enrollment open, Metastases:
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov) - Jul 14, 2022
P1/2
, N=267, Recruiting,
Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd
Conclusions PRJ1 Not yet recruiting --> Recruiting
||
||||||||
PRJ1-3024
/
MingMed Biotech
Enrollment open, Metastases:
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov) - Apr 12, 2022
P1
, N=46, Recruiting,
Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
|||||
|||||
PRJ1-3024
/
MingMed Biotech
New P1/2 trial, Metastases:
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov) - Apr 7, 2022
P1/2
, N=267, Not yet recruiting,
Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd
|
|||||||||
PRJ1-3024
/
MingMed Biotech
New P1 trial, Metastases:
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
(clinicaltrials.gov) - Dec 15, 2021
P1
, N=46, Not yet recruiting,
Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd